Delcath Systems, Inc. (DCTH)

0.11
OTC Markets
Prev Close 0.11
Day Low/High 0.09 / 0.11
52 Wk Low/High 0.06 / 10.30
Exchange OTC Markets
Shares Outstanding 18.28B
Market Cap 1.97M
Div & Yield N.A. (N.A)

Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies

Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months

Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential Of Delcath Investigational PHP Therapy

Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...

3 Breakout Stocks Under $10 to Trade Now

3 Breakout Stocks Under $10 to Trade Now

These under-$10 stocks are within range of triggering breakout trades.

Delcath Systems (DCTH) Weak On High Volume

Delcath Systems (DCTH) Weak On High Volume

Trade-Ideas LLC identified Delcath Systems (DCTH) as a weak on high relative volume candidate

5 Active Under-$10 Stocks to Buy Now

5 Active Under-$10 Stocks to Buy Now

When a stock makes a large move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Northwest Bio's German Smokescreen Obscures DCVax Problems

Northwest Bio's German Smokescreen Obscures DCVax Problems

Northwest Bio received good news from Germany in February but didn't tell investors until Monday.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude

Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude

Momentum traders don't understand FDA regulations.

First Week Of DCTH March 2014 Options Trading

First Week Of DCTH March 2014 Options Trading

Investors in Delcath Systems Inc. saw new options begin trading this week, for the March 2014 expiration.

Ask SUT

This week, David Peltier answers questions about two model portfolio names and two other specific low-dollar stocks.

Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors Of Upcoming Deadlines In Shareholder Litigation Involving Delcath Systems, Inc., Amyris, Inc., Nam Tai Electronics, Inc. And Accretive Health, Inc.

Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors Of Upcoming Deadlines In Shareholder Litigation Involving Delcath Systems, Inc., Amyris, Inc., Nam Tai Electronics, Inc. And Accretive Health, Inc.

Holzer Holzer & Fistel LLC reminds investors of upcoming deadlines for applications to serve as lead plaintiff in securities class action lawsuits against Delcath Systems, Inc.

Law Offices Of Todd M. Garber Announces Class Action Lawsuit Against Delcath Systems, Inc.

Law Offices Of Todd M. Garber Announces Class Action Lawsuit Against Delcath Systems, Inc.

The Law Offices of Todd M. Garber announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the “Class”) comprising all ...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

2013 FDA Drug Approval Calendar

2013 FDA Drug Approval Calendar

An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.

Leaders of <I>TheStreet's</I> Drug Approval Contest

Leaders of TheStreet's Drug Approval Contest

This group of contestants have nearly perfect records picking FDA and European drug approvals.

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock futures are looking to rebound from losses in the prior session.

Aveo, Delcath FDA Panel Live Blog

Aveo, Delcath FDA Panel Live Blog

Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems

FDA Tells Delcath No Approval Without New Clinical Trial

FDA Tells Delcath No Approval Without New Clinical Trial

Delcath's liver-tumor device uses a filter that FDA says does not work.

Prepping for Aveo, Delcath FDA Panels

Prepping for Aveo, Delcath FDA Panels

It's a big week for Aveo and Delcath, starting Tuesday with FDA reviews of their respective cancer products.

Biotech's Next Big Thing: Aveo

Biotech's Next Big Thing: Aveo

TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.

Most Profitable Second Quarter Biotech Stocks

Most Profitable Second Quarter Biotech Stocks

A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.

Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm

Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Best And Worst FDA Drug Approval Stocks of 2013

Best And Worst FDA Drug Approval Stocks of 2013

Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who will be the premier prognosticator of FDA drug approvals in 2013?

3 Pharma Stocks Under $5 Trading Higher

3 Pharma Stocks Under $5 Trading Higher

Stocks making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility.

2013 FDA Drug Approval Decision Calendar

2013 FDA Drug Approval Decision Calendar

A list of stocks with drugs expecting FDA decisions in 2013